Recruiting

Observational Study

Sponsor:

UCLA

Code:

NCT07284082

Conditions

HIV

Menopause

Cardiovascular (CV) Risk

Carotid Arteriosclerosis

Body Composition

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Whole body MRI

Study Details

Brief summary:

Menopause is associated with the acceleration of many comorbidities, including cardiovascular disease. Whether HIV and menopause together increase cardiovascular disease risk is a key knowledge gap. The goal of this observational study is to address this knowledge gap by looking at the role of menopause on cardiovascular disease risk factors such as insulin resistance, hypertension, hyperlipidemia, and carotid atherosclerosis using previously collected data. The investigators will look at underlying causes for cardiovascular diseases worsening in menopausal women with HIV by looking at the role of increased inflammation in the body and whether this is altered by weight. The investigators achieve this by enrolling participants who are willing to undergo a whole body MRI.

Conditions

HIV

Menopause

Cardiovascular (CV) Risk

Carotid Arteriosclerosis

Body Composition

Study ID

NCT07284082

Start date

Apr 17, 2026

Status verified date

Apr, 2026

Completion date

Mar 1, 2030

Anticipated

Primary completion date

Mar 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • 90 non-pregnant women with HIV (approximately 30 in each menopausal phase) from the San Francisco MWCCS site.

Exclusion Criteria:

  • Women who are not virally suppressed (HIV RNA >200 copies/mL)
  • Women who are not on antiretroviral therapy
  • Women who have a history of hysterectomy or oophorectomy
  • Women who are receiving treatment for active cancer or tuberculosis

Study Design

Enrollment

90 participants

Anticipated

Interventions and Outcome Measures

Arms

MACS-WIHS Combined Cohort Study

Interventions

Whole body MRI

Whole body MRI will be performed as part of a study protocol

Primary outcome measure

  • Markers of immune activation and inflammation [ Time Frame: These markers will be measured from blood work collected at the scheduled study visit [Day 1] close to the time of MRI and thus will be collected at only one time point. ]

Central Contacts and Locations

Central contacts

Rebecca A Abelman, MD

415-221-4810rebecca.abelman@ucsf.edu

Stacy Polos

415-689-0915stacy.polos@ucsf.edu

Locations

University of California, San Francisco

Recruiting

San Francisco, California, United States, 94110

Contacts

Rebecca A Abelman, MD

415-223-4810rebecca.abelman@ucsf.edu

More Information

Sponsor

University of California, San Francisco

Last update posted

Apr 22, 2026

Last verified

Apr, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of California, San Francisco on 2026-04-22.